RENO, NV, Aug. 17, 2021 (GLOBE NEWSWIRE) -- XcelPlus International Inc. (OTC PINK: XLPID) announced today that it has received a signed letter of intent to build plasma gasifiers for a landfill removal consortium based in India.
Here is the original post:
XcelPlus International inks letter of intent to build plasma gasifiers for India landfill removal consortium
New 7mm insertion profile, combined with company’s proprietary Adaptive Geometry™ technology, are designed to respect patients’ neural, vascular, bony and soft tissue anatomy both during and after insertion to promote long-term stability New 7mm insertion profile, combined with company’s proprietary Adaptive Geometry™ technology, are designed to respect patients’ neural, vascular, bony and soft tissue anatomy both during and after insertion to promote long-term stability
See the original post here:
Accelus Launches Ultra-Low-Profile FlareHawk7™ Expandable Cage Implant and Innovative Instruments to Support Endoscopic, MIS Lumbar Fusion...
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progress update for the second quarter 2021.
See the original post here:
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and...
-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --
Follow this link:
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
KEEGO HARBOR, Mich., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today issues a letter to shareholders from Chief Executive Officer Andrew Dahl.
Continued here:
Zivo Bioscience, Inc. Issues Letter to Shareholders
COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 25, 2021 at 4:30 p.m. Eastern Time (ET) to review its second quarter 2021 financial results and provide a business update.
Go here to see the original:
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSK’s JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
See the article here:
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
View post:
ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units
TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that Revive has entered into an exclusive license agreement (the “Agreement”) with Puerto Rico Science Technology and Research Trust (“PRSTRT”), representing Universidad Central del Caribe (“UCC”) and St. Jude Children’s Research Hospital (“St. Jude”), for the intellectual property (International Patent Application No. PCT/US2020/017053/) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization. Researchers at St. Jude and UCC have characterized medicinal mushroom Ganoderma lucidum compounds with anti-cancer activity, specifically signi?cant activity against breast cancer, thus having the potential to treat the most aggressive types of breast cancers such as triple negative breast cancer and in?ammatory breast cancer.
See the rest here:
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer
PORTLAND, Ore., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces it will report its second quarter 2021 results on Thursday, August 26, 2021 after market close.
Continue reading here:
Chalice Brands Ltd. Announces Timing of Its Second Quarter Earnings Results